Dear Editor, Temsirolimus is a selective inhibitor of the cell proliferation promoting intracellular protein mTOR (mammalian target of rapamycin). Its activity in lymphatic malignancies has first been demonstrated in relapsed mantle-cell lymphoma [1] . Further studies confirmed activity in this lymphoma entity and established a weekly dosage of 75 mg as approved treatment regimen [2] , although a weekly dose of 25 mg remains an effective treatment option [3] . Experience with temsirolimus in other entities of non-Hodgkin's lymphoma (NHL) is limited to a phase II study in recurrent diffuse large B-cell lymphoma (DLCBL), follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma [4] . In 19 evaluable patients with DLCBL and a median of ≥2 prior treatment lines, a remarkable overall response rate of 42% was observed with a weekly temsirolimus dosage of only 25 mg.
A 44-year-old woman was diagnosed with diffuse large B-cell lymphoma NHL limited to the tongue base (stage IBE) in June 2003. After initial treatment with six cycles of doseintensified cyclophosphamide, adriamycin, vincristine, etoposide, and prednisolone (Hi-CHOEP), a complete response was achieved. The patient relapsed in October 2006 with intrathoracic and abdominal manifestations. Salvage therapy included three cycles of rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) followed by high-dose carmustine, etoposide, cytarabine, melphalan (HD-BEAM) and autologous stem-cell transplantation resulting in complete response. In July 2008, second relapse occurred with cervical and abdominal lymph node enlargements. Treatment was initiated with five cycles of rituximab and bendamustine yielding another complete response. Remission, however, was short-lived, and in January 2009, disease recurred. Sequential treatment included one cycle of rituximab, dexamethasone, high-dose cytarabine, cisplatin (R-DHAP) and one cycle of rituximab, high-dose cytarabine, mitoxantrone (dose-modified R-HAM) in reconfirmed CD20-positive disease followed by a second high-dose protocol with (Fig. 1a, b) . Temsirolimus infusions were continued, but unfortunately, tumor progression was observed 4 weeks later.
The very favorable response in our patient with highly pretreated refractory DLCBL, though short-lived, supports the evidence of a high activity of temsirolimus in NHL including DLCBL. Further investigations are clearly warranted, preferably in less advanced disease and in combi- 
